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ORIGINAL ARTICLE
Acute WNT signalling activation perturbs differentiation within
the adult stomach and rapidly leads to tumour formation
S Radulescu1, RA Ridgway1, J Cordero1, D Athineos1, P Salgueiro1,2, R Poulsom3, J Neumann4, A Jung4, S Patel5, J Woodgett5, N Barker2,
DM Pritchard6, K Oien7 and OJ Sansom1
A role for WNT signalling in gastric carcinogenesis has been suggested due to two major observations. First, patients with germline
mutations in adenomatous polyposis coli (APC) are susceptible to stomach polyps and second, in gastric cancer, WNT activation
confers a poor prognosis. However, the functional signiﬁcance of deregulated WNT signalling in gastric homoeostasis and cancer is
still unclear. In this study we have addressed this by investigating the immediate effects of WNT signalling activation within the
stomach epithelium. We have speciﬁcally activated the WNT signalling pathway within the mouse adult gastric epithelium via
deletion of either glycogen synthase kinase 3 (GSK3) or APC or via expression of a constitutively active b-catenin protein. WNT
pathway deregulation dramatically affects stomach homoeostasis at very short latencies. In the corpus, there is rapid loss of parietal
cells with fundic gland polyp (FGP) formation and adenomatous change, which are similar to those observed in familial
adenomatous polyposis. In the antrum, adenomas occur from 4 days post-WNT activation. Taken together, these data show a
pivotal role for WNT signalling in gastric homoeostasis, FGP formation and adenomagenesis. Loss of the parietal cell population and
corresponding FGP formation, an early event in gastric carcinogenesis, as well as antral adenoma formation are immediate effects
of nuclear b-catenin translocation and WNT target gene expression. Furthermore, our inducible murine model will permit a better
understanding of the molecular changes required to drive tumourigenesis in the stomach.
Oncogene (2013) 32, 2048–2057; doi:10.1038/onc.2012.224; published online 4 June 2012
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INTRODUCTION
Stomach cancer is the fourth most common cancer worldwide
and the second most common cause of death with a very poor
5-year survival rate (usually of under 15%) due to the late stage
at time of diagnosis.1,2 Over 90% of gastric cancers are
adenocarcinomas and, based on histological features, can be
divided into two types: intestinal and diffuse.3–5 The incidence of
both types varies greatly between groups with differences linked
to age of diagnosis and gender; however, the intestinal type is
slightly more common overall.6 In intestinal-type gastric cancer,
the sequence of patho-physiological changes is well established
with Helicobacter pylori infection causing chronic inﬂammation of
the mucosa followed by gastric atrophy, intestinal metaplasia,
dysplasia and ultimately adenocarcinoma.7–9 However, o1% of
individuals infected with H. pylori will go on to develop gastric
cancer.10 Diffuse-type stomach cancer is characterised by the
downregulation or loss of the cell adhesion molecule
E-cadherin.11,12 This is an early event in tumourigenesis and
individuals carrying germline mutations in the CDH1 gene
develop hereditary diffuse gastric cancer.13
Deregulation of the WNT signalling pathway has been
implicated in numerous cancers; however, only in colorectal
cancer (CRC) it has been shown to be the driving mutation.14–18 In
CRC, adenomatous polyposis coli (APC) is the key tumour
suppressor protein and is mutated in B80% of sporadic cancers.
Moreover, germline heterozygosity of this gene leads to familial
adenomatous polyposis (FAP).19–21 FAP patients acquire numerous
colonic and rectal polyps early in life, which will then progress to
carcinoma by 40–50 years of age.22,23 Deregulated WNT signalling
is thought to be oncogenic through the upregulation of T-cell
factor (TCF)/lymphoid enhancer factor (LEF) transcriptional targets.
Brieﬂy, in the absence of WNT ligand, b-catenin is targeted for
degradation by a complex containing APC, glycogen synthase
kinase 3 (GSK3) and axin.24 In this situation, GSK3 phosphorylates
b-catenin, which is then degraded by the proteasome. In the
presence of a WNT signal, this complex is destabilised and
b-catenin translocates to the nucleus.24,25 Together, b-catenin and
TCF/LEF activate a large number of WNT target genes including
C-MYC, SOX9 and CYCLIN D1.26–28 Thus, inactivating mutations of
APC or activating mutations in b-catenin (which prevent its
phosphorylation by GSK3) lead to the induction of WNT signalling
and target gene activation. Indeed, we have shown that within the
murine small intestine APC loss alone is sufﬁcient to drive
adenoma formation when targeted to the intestinal stem cell.29
Outwith CRC, FAP patients also develop fundic gland polyps
(FGPs) and these can rarely progress to carcinoma.30–32
Importantly, these FGPs have been shown to lose the remaining
wild-type (WT) APC allele, a process also responsible for initiation
of intestinal and colonic adenomas in the same patients.33,34
Furthermore, sporadic FGPs tend to have b-catenin activating
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mutations, suggesting that deregulation of the WNT signalling
pathway may be central to both hereditary and sporadic tumour
formation.33–37
In gastric carcinogenesis, APC mutations have been found in
both benign and malignant stomach tumours (of the intestinal as
well as diffuse types) with up to 25% of gastric adenomas
exhibiting somatic mutations in this gene.38–41 b-Catenin
activating mutations are also found in intestinal- and diffuse-
type gastric cancer with 30% of tumours showing nuclear
accumulation.35,38,42–44 Furthermore, nuclear b-catenin correlated
with an invasive phenotype in intestinal-type tumours.45 However,
the mechanism by which WNT signalling promotes tumour
progression is poorly understood.
Therefore, in order to dissect out the functional role of the WNT
pathway in this cancer, we have directly activated WNT signalling in
the gastric epithelium either through inactivation of either APC or
GSK3 or expression of a constitutively active b-catenin allele. In all
cases, activation of WNT signalling had a marked impact on stomach
homoeostasis. Our results demonstrate that nuclear b-catenin
accumulation is sufﬁcient for antral adenoma formation, while
within the corpus activation of WNT signalling resulted in the loss of
the parietal cell population with FGP formation as well as
adenomatous change. Therefore, our data deﬁnitively prove that
WNT activation can act as an initiating step in gastric tumourigenesis.
RESULTS
The AHCreER transgene drives Cre recombinase expression within
the gastric epithelium
To obtain deregulation of WNT signalling within the mouse adult
stomach, we used a Cre recombinase under the control of the
Cyp1A1 promoter fused to the OEstrogen Receptor (ER), the AHCreER
construct.46 This Cre is inducible by an i.p. (intraperitoneal) injection
of b-naphthoﬂavone and tamoxifen. To obtain maximum
recombination efﬁciency four i.p. injections were administered over
2 days. Figures 1a and b shows Cre immunohistochemistry (IHC) in
stomach tissue taken at day 1 post-induction, which conﬁrms Cre
expression within the gastric epithelium.
To assess the recombination efﬁciency using this regime in mice
carrying the AHCreER transgene, these mice were crossed to mice
carrying at the Rosa26 locus either a lacZ or red ﬂuorescent
protein (RFP) reporter construct. Figure 1c shows stomach whole-
mount staining for b-galactosidase activity 4 days following Cre
induction as well as in-vivo imaging of RFP expression at the same
time point (day 4) and a later time point (day 10).
To determine the precise cell lineages where recombination
was occurring, we crossed the AHCreER transgenic mice to the
Z/EG reporter mice. The Z/EG transgenic reporter contains a loxP
ﬂanked lacZ cassette followed by a GFP reporter gene.47 Thus,
following Cre-mediated excision, GFP is expressed. Figure 1e
shows GFP IHC staining at an early time point, day 4 post-
induction, and at a later time point, day 20 post-induction. GFP
expression was found in individual cells in both the fundic and
antral glands at day 4 post-induction. Furthermore, by day 20
following recombination, whole gastric units were now GFP
positive, demonstrating that Cre expression occurred in precursor
or stem cells capable of generating the entire range of
differentiated cell types.
Stem cell recombination was also achieved using a much lower
induction regime of only one i.p. injection of b-naphthoﬂavone
and tamoxifen with individual gastric pits still expressing RFP 60
days after the single injection (Figure 1d).
Activation of WNT signalling in the antral glands leads to rapid
adenoma formation
As both APC and b-catenin are mutated in a large number
of gastric cancers, we next characterised the effect of WNT
activation within the adult stomach epithelium. For this we used
three different ways of driving deregulated WNT signalling:
either by deleting the WNT negative regulators APC or GSK3 or
activating b-catenin by deleting exon 3, which contains
the GSK3 phosphorylation sites hence preventing its degradation.
Therefore, we crossed the AhCreERþ mice to either APCﬂ/ﬂ,
Catnbexon3ﬂ/exon3ﬂ or GSK3 alphaﬂ/ﬂ betaﬂ/ﬂ mice and obtained
the following experimental mice: AhCreERþ APCﬂ/ﬂ, AhCreERþ
Catnbexon3ﬂ/exon3ﬂ and AhCreERþ GSK3 alphaﬂ/ﬂ betaﬂ/ﬂ. Table 1
contains an overview of the incidence and phenotype observed in
experimental versus control mice along with time points and
number of mice used per experiment.
First, we investigated the immediate phenotype of WNT
signalling deregulation (using the maximal Cre induction detailed
above) at day 4 post-induction in the stomach antrum. Figure 2a
shows that in all three mouse models there were individual cells
with nuclear b-catenin showing deregulation of the WNT pathway
as WT antrum lacks nuclear b-catenin. Remarkably, even at this
very early time point, there are already small hyperproliferative
microadenomas. This indicates that the antral region is very
sensitive to nuclear b-catenin accumulation.
These mice were then aged until they showed signs of illness.
As shown in Figures 2b–e, the small lesions observed at day 4
progress to large adenomas, which due to their proximity to the
small intestine can cause obstruction. These adenomas are
reminiscent of intestinal adenomas observed when APC or
b-catenin are mutated and can be classiﬁed as intestinal-type
gastric adenoma.48,49 Furthermore, when stomachs from mice
where WNT activation had occurred were collected and opened,
the glandular region was greatly thickened compared with Cre
negative controls (Figure 2c).
To conﬁrm the activation of the WNT pathway, we looked by
IHC at the expression of a number of WNT target genes in these
lesions. Compared with normal tissue, these adenomas express
high levels of c-MYC and Sox9 as well as markers of proliferation
like Mcm2 and ki67, which are now localised on the surface of the
glands (Figure 2e; Supplementary Figure 1).
We also looked at mRNA levels in whole stomach tissue and
found WNT targets Achaete scute-like 2 (Ascl2), Cyclin D1 (CCnd1),
Leucine-rich-repeat-containing G-protein-coupled receptor 5
(Lgr5) and Axin2 were signiﬁcantly upregulated (Figure 3a).
To conﬁrm that nuclear b-catenin accumulation is present in
stomach lesions from FAP patients, we also performed b-catenin
IHC on this tumour tissue. Biopsy samples from patients with
intestinal-type gastric adenomas indeed conﬁrm that nuclear
b-catenin accumulation and expression of the WNT target Sox9 is
a feature of this type of neoplasia (Figure 3b).
Activation of WNT signalling in the corpus of the stomach leads to
fundic gland polyposis and adenomatous change
In contrast to the antrum, within the corpus region of the stomach
resides the parietal cell lineage. These cells are responsible for the
acidic pH of the stomach via the activity of their membrane-bound
proton pumps.50 A common pre-neoplastic lesion found in the
corpus region in FAP patients is the FGP. This lesion is
characterised by enlarged glands with cystic transformation
lined by parietal cell and chief cells.51
Deregulation of WNT signalling (through either APC or GSK3
loss of b-catenin activation) led to progressive loss of the parietal
cell population concomitant with FGP formation interspersed with
adenomatous change. Figures 4a and b show wide spread fundic
gland cysts, characteristic of fundic gland polyposis, together with
tubular adenomatous structures identical to the adenomas
observed in the antrum. These lesions show a dramatic increase
in nuclear b-catenin accumulation throughout (Figure 4c). Impor-
tantly, this was in contrast to the WT corpus where nuclear
b-catenin was absent (Supplementary Figure 2). Similar to the
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Figure 1. The AHCreER transgene drives recombination in the gastric epithelium. (a) IHC detecting Cre expression in the antrum of AhCreERþ
versus AhCreER mice at day 1 post-induction. Scale bar, 10 mm. (b) IHC detecting Cre expression in the corpus of AhCreERþ versus AhCreER
mice at day 1 post-induction. Scale bar, 10 mm. (c) Top: b-Galactosidase staining of whole-mount stomachs from AhCreER Rosa26lacZ (left) and
AhCreERþ Rosa26lacZ (right) mice at day 4 post-induction. Bottom: In-vivo RFP fluorescence imaging of AhCreER Rosa26tdRFP (left) and
AhCreERþ Rosa26tdRFP (right) mice at day 4 post-induction (unopened stomach) and at day 10 post-induction (opened stomach). F,
forestomach; C, corpus; A, antrum; SI, small intestine; BF, bright field. Forestomach tissue is auto-fluorescent. (d) In-vivo RFP fluorescence
imaging of AhCreERþ Rosa26tdRFP (left) and AhCreER Rosa26tdRFP (right) mice at day 60 post-induction following a single injection of the
inducing agent. Individual gastric pits are positive for RFP (bottom high magnification panel). (e) IHC detecting GFP expression in the stomach
of AhCreERþ Z/EG mice at day 4 and 20 post-induction. Left two panels, antrum. Right two panels, corpus. Scale bar, 20 mm.
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antrum, these cells also expressed c-MYC and Sox9 WNT target
genes as well as Mcm2 and ki67 proliferation markers (Figure 4c).
It is well known that loss of parietal cell function through acid
suppression therapy can lead to fundic gland polyposis;52,53
however, we wanted to investigate the mechanistic basis of how
WNT activation led to a marked reduction in the number of the
parietal cells. First, we investigated if recombination was occurring
in the parietal cell population. Figure 5a shows at day 3 post-
induction nuclear b-catenin accumulation in parietal cells. To
conﬁrm this, we used double staining with a parietal cell speciﬁc
marker, the proton pump. We observe that terminally differen-
tiated parietal cells can now display nuclear b-catenin accumula-
tion. At the same time, double staining for the proliferation marker
Mcm2 and the proton pump highlights the fact that these cells are
now primed to enter the cell cycle. However, very few cells stained
positive for both Mcm2 and the proton pump showing that this
potential re-entry into the cell cycle is a rare event.
Another question that arose from this observation was whether
the parietal cells were the only cells in the corpus where gene
deletion occurred. To investigate this, we used double staining to
look at other cell types and their b-catenin expression pattern. Co-
staining with Muc 5A, a marker of foveolar cells, indicated that
recombination occurs also in this cell type (Figure 5a). However,
the fate of these recombined foveolar cells is not known.
In conclusion, the nuclear b-catenin-positive cells present in the
FGPs may have originated from a terminally differentiated cell
population within the corpus, which have lost their cell type
speciﬁc markers and are now able to proliferate.
It is interesting to note that when we activated one copy of
b-catenin in our AhCreERþ Catnbexon3ﬂ/þ and examined the
parietal cell population, we now found many cells expressing
various degrees of nuclear b-catenin accumulation
(Supplementary Figure 3). These cells persisted up to 20 days
post-induction without losing their parietal cell speciﬁc properties.
This may suggest that the precise level of nuclear b-catenin
determines the fate of these cells. Deletion of both copies of APC
or GSK3 a and b or activation of both copies of b-catenin will
induce much higher levels of nuclear b-catenin, since the
destruction complex cannot form without either of these proteins.
However, the activated b-catenin in the AhCreERþ Catnbexon3ﬂ/þ
mice cannot be degraded but it may still bind this destruction
complex therefore slowing down the kinetics of its nuclear
translocation.
In our experimental setup, low-level expression of the Cre
recombinase in other tissues precluded aging of these mice
sufﬁciently to observe the progression of these parietal cells with
lower nuclear b-catenin. However, a recently described mouse
model allows targeting gene deletion speciﬁcally to parietal cells,
using a sequence from the promoter of the parietal speciﬁc
proton pump.54 In future, this may allow the study of the effects of
low/intermediate levels of nuclear b-catenin in parietal cells over
the long term.
Although the tumours express the intestinal stem cell marker Lgr5,
tumour formation is greatly accelerated when compared with
microadenomas initiated by WNT signalling deregulation in the
Lgr5 lineage
It has recently been reported that the orphan G-protein-coupled
receptor Lgr5 (GPR49), a marker of intestinal stem cells, is
expressed in the adult antral stomach but not in the glands of
the corpus.55,56 Lgr5þ ve cells can give rise to all cell types in the
antrum and they represent a gastric stem cell population. In the
intestine, deletion of APC in the Lgr5þ ve cells gives rise to rapid
tumourigenesis, while APC loss in the Lgr5 ve population does
not result in cancer progression.29 This argues for a requirement to
have a stem cell as a cancer-initiating cell.
To investigate whether our gastric adenomas also displayed
stem cell origins we examined Lgr5 expression. Interestingly,
in situ hybridisation (ISH) shows that the adenomas found in the
corpus express high levels of Lgr5 (Figure 5b). This is unexpected
since Lgr5 is only present during the developmental stage of the
corpus. This indicates that these cells are now adopting a
‘progenitor-cell’ signature, which may highlight de-differentiation
as a potential tumour initiation process in the corpus.
However, if we are to compare the latency of antral
tumour formation between AhCreERþ APCﬂ/ﬂ or AhCreERþ
Catnbexon3ﬂ/exon3ﬂ mice to Lgr5creERT2þ APCﬂ/ﬂ and Lgr5creERT2þ
Catnbexon3ﬂ/exon3ﬂ, this is much more rapid in mice carrying the
Table 1. Incidence of b-catenin-positive lesions at different time points
Genotype Time point Number of mice with nuclear b-catenin-positive lesions
Antrum—microadenoma
(MA) and adenoma(A)
Corpus—fundic gland polyps (FGP)
and adenomatous change (AC)
Experimental mice
AhCreERþ APCfl/fl Day 4 MA 8 out of 8 0 out of 8
Day 6 MA 3 out of 3 0 out of 3
Day 12 A 3 out of 3 FGP and AC 3 out of 3
AhCreERþ Catnbexon3fl/exon3fl Day 4 MA 4 out of 4 0 out of 4
Day 11 A 5 out of 5 FGP and AC 5 out of 5
AhCreERþ GSK3 Day 4 MA 8 out of 8 0 out of 8
Day 6 MA 3 out of 9 FGP 2 out of 9
alphafl/fl betafl/fl A 6 out of 9 AC 3 out of 9
Day 8 A 6 out of 6 FGP and AC 6 out of 6
Day 12 A 5 out of 5 FGP and AC 5 out of 5
Control mice
AhCreERþ Day 4 0 out of 4 0 out of 4
Day 6 0 out of 3 0 out of 3
Day 12 0 out of 3 0 out of 3
AhCreERþ Catnbexon3fl/þ Day 4 0 out of 3 0 out of 3
Day 6 0 out of 5 0 out of 5
Day 21 0 out of 3 0 out of 3
AhCreERþ GSK3 alphafl/fl betafl/þ Day 6 0 out of 3 0 out of 3
Day 8 0 out of 3 0 out of 3
Day 12 0 out of 5 0 out of 5
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AHCreER transgene (Figure 5c). Indeed, the Lgr5creERT2 mice only
developed microadenomas in the antral stomach in mice aged up
to 100 days (these mice had to be killed due to intestinal adenoma
formation) while AHCreER mice had small adenomas from day 4
post-induction, which progress to whole stomach lesions by days
10–12 post-induction. Therefore, unlike in the intestine, the Lgr5
antral stem cell population seems less sensitive to WNT pathway
activation. Lack of Lgr5 expression in the corpus makes it
Figure 2. Activation of WNT signalling in the antral glands leads to rapid adenoma formation. (a) IHC detecting b-catenin showing nuclear
localisation in antrum tissue from AhCreERþ APCfl/fl (APC), AhCreERþ Catnbexon3fl/exon3fl (Bcat) and AhCreERþ GSK3 alphafl/fl betafl/fl (GSK3) mice
versus AhCreERþ (WT) only mice at day 4 post-induction. Scale bar, 10 mm. (b) Hþ E stain of an antral tumour from AhCreERþ GSK3 alphafl/fl
betafl/fl (GSK3) mouse at day 136 post-induction (single inducer injection). Scale bar, 200 mm. (c) In-vivo RFP fluorescence imaging of AhCreERþ
Rosa26tdRFP APCfl/fl (left) and AhCreER Rosa26tdRFP APCfl/fl (right) mice at day 10 post-induction. Arrows indicate thickened areas of glandular
stomach. BF, bright field. (d) Haematoxylin and eosin (Hþ E) stain of an antral tumour from AhCreERþ GSK3 alphafl/fl betafl/fl (GSK3) mouse at
day 8 post-induction with a high magnification panel (right). Scale bar, 20 mm. (e) Antral neoplasia in AhCreERþ GSK3 alphafl/fl betafl/fl mice at
day 8 post-induction. IHC staining reveals high levels of nuclear b-catenin with corresponding c-MYC and Sox9 staining, as well as high levels
of proliferation (BrdU and ki67-positive cells). Scale bar, 50 mm.
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impossible to use the Lgr5creERT2þ construct for a similar
comparison in the corpus.
DISCUSSION
Our data show that deregulation of the WNT signalling pathway
strongly perturbs gastric homoeostasis in both the corpus and the
antrum. In many ways, the antral phenotype recapitulates
previous ﬁndings in the small intestine where deregulation of
WNT signalling alone is sufﬁcient for benign tumourigen-
esis.29,48,57 Indeed, the phenotype of hyperproliferation is also
reminiscent of APC deletion in the small intestine. In the corpus,
the loss of parietal cells appears to predispose to FGP formation, a
situation akin to humans, where both proton pump inhibitors
(which block parietal cell function) and germline heterozygosity
for APC predispose to fundic gland polyposis.52 However, in both
the antrum and the corpus, we failed to see conversion to
malignant gastric cancer. This argues that activation of WNT
signalling is not sufﬁcient to drive malignancy.
In contrast to CRC, the mutations that drive gastric cancer are
much more unclear. It has been suggested that the two major
predisposing factors to gastric cancer, H. pylori infection or
germline mutations in E-cadherin, both may drive tumourigenesis
in part through activation of WNT signalling.58,59 In-vitro H. pylori
infection of cells leads to increased nuclear levels of b-catenin as
well as TCF/LEF transactivation.60,61 This has been suggested to
be due to inhibition of GSK3 activity via the PI3K (phos-
phatidylinositol 3-kinase) pathway, which results in b-catenin
stabilisation.62 However, linking this inhibitory phosphorylation of
GSK3 by v-akt murine thymoma viral oncogene homologue (AKT)
to WNT signalling pathway activation is controversial as it appears
that this pool of GSK3 is functionally distinct to the pool of GSK3
that binds APC.63 Instead, it is likely that this phosphorylation of
GSK3 is marking high PI3K activity, which itself can activate WNT
signalling through an activating phosphorylation of b-catenin.64
H. pylori also induces phosphorylation of the WNT co-receptor
low-density lipoprotein receptor-related protein 6, which plays a
crucial role in WNT signal transduction.65 This is dependent on
Dishevelled (Dvl) 2 and 3 proteins, which recruit GSK3 and Axin2
away from the b-catenin destruction complex. Moreover, another
study has suggested that H. pylori may induce WNT signalling in a
met proto-oncogene (c-Met)-dependent manner.66 Despite these
multiple ways in which H. pylori can induce WNT signalling, our
phenotypes following APC or GSK3 loss are distinct from the
inﬂammatory response and gastritis induced by H. pylori. There are
probably multiple reasons for this but the levels of deregulated
WNT target gene expression induced by APC mutations are likely
to be much greater than the levels induced by H. pylori infection. It
is thus interesting to note from our results that activation of a
single copy of b-catenin does not induce such a robust phenotype
as two copies or loss of APC or GSK3. Thus, while activation of one
copy of b-catenin leads to its nuclear accumulation from very early
stages, progression to adenoma is much slower compared with
APC or GSK3 deletion. Again this may be a direct result of b-
catenin levels in the nucleus not being sufﬁcient for malignant
transformation, at least not at this early stage after gene mutation.
It is probable that in the human context, a variety of genetic and
environmental factors contribute to the b-catenin nuclear
presence in high enough quantity to induce tumourigenic WNT
activation. In agreement with this, premise studies have shown
that GSK3 b phosphorylation and inactivation also correlates with
cancer progression in human tumours.67 Furthermore, another
WNT pathway component upregulated in advanced gastric cancer
is the Wnt1 ligand.68 Elegant mouse studies by the Oshima group
have shown that in the mouse co-activation of WNT (via
expression of the WNT1 ligand) and the PGE2 (prostaglandin E2)
Figure 3. Activation of WNT signalling in the stomach correlates with the phenotype observed in FAP patients with intestinal-type adenomas.
(a) Relative expression (qRT–PCR levels) of WNT target genes Achaete scute-like 2 (Ascl2), Cyclin D1 (Ccnd1), Leucine-rich-repeat-containing
G-protein-coupled receptor 5 (Lgr5), Naked cuticle homologue 1 (Nkd1) and Axin2. mRNA levels were measured in whole stomach tissue from
AhCreERþ GSK3 alphafl/fl betafl/fl (experimental) compared with AhCreERþ GSK3 alphafl/fl betafl/þ (control) mice at day 6 post-induction.
Po0.001 apart from Nkd1 Po0.097. (b) IHC staining for b-catenin and Sox9 in gastric lesions from FAP patients. Left two panels, intestinal-type
adenoma; right two panels, intestinal-type metaplasia. Scale bar, 10 mm.
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pathway in a constitutive manner results in invasive gastric
adenocarcinoma formation by 1 year.69 In contrast, WNT1
expression alone resulted in pre-neoplastic lesions at 7–18
weeks of age but never tumourigenesis. This is in good
agreement with our data that shows that activation of a single
copy of b-catenin does not result in histological changes up to 3
weeks after activation. In spite of the fact that both our AhCreERþ
Catnbexon3ﬂ/þ mice and the CK19 Cre-Wnt1 mice show higher
levels of b-catenin with nuclear accumulation this is not sufﬁcient
to trigger adenoma formation. However, in our study when we
activate both copies of b-catenin or loss of both copies of Apc this
now reaches the required WNT threshold to initiate fundic gland
polyposis and adenomatous change. For sporadic gastric cancer,
it is much more likely that WNT activation will cooperate with
other pathways (for example WNT and PGE2) in driving tumour
progression.
Within human gastric cancer, loss of function mutations in APC
or activating mutations in b-catenin are often associated with poor
prognosis. The Wnt1 ligand is also overexpressed at the later
stages of gastric carcinoma as opposed to early on. These data are
in contrast to our data presented here where mice develop benign
tumours. It is thus likely that in human gastric cancers, mutations
that deregulate WNT signalling occur post-initiation and it will be
of interest to combine APC loss or b-catenin activation in the
Figure 4. Activation of WNT signalling in the corpus of the stomach leads to FGPs with progressive parietal cell loss. (a) Hþ E stain of corpus
region from AhCreERþ GSK3 alphafl/fl betafl/fl (GSK3) mice at days 4, 6 and 12 post-induction (top, low magnification; bottom, high
magnification). Day 4—areas of the corpus show a reduction in the number of parietal cells (red arrows). Day 6—both FGPs and regions of
adenomatous change are present in the corpus (red arrow marks parietal cells lining a fundic cyst). Day 12—widespread fundic gland
polyposis and adenomatous change in the corpus. Scale bar, 50 mm. (b) IHC detecting Hþ–Kþ–ATPase expression marking parietal cells in
AhCreERþ GSK3 alphafl/fl betafl/fl versus AhCreERþ (Control) mice at days 4, 6, 8 and 12 post-induction. Scale bar, 50 mm. (c) FGPs and
adenomatous change in AhCreERþ GSK3 alphafl/fl betafl/fl mice at day 12 post-induction. IHC staining for b-catenin, c-MYC, Sox9, Mcm2, ki67
and Alcian Blue Periodic Acid Schiff (AB/PAS). Scale bar, 50 mm.
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gastric epithelium with other mutations that occur in gastric
cancer to see if we can develop a representative model of the later
stages of gastric carcinoma.
In conclusion, our data demonstrate that WNT activation can act
as an initiator in gastric neoplasia. Both deletion of APC or GSK3 a
and b lead to immediate nuclear b-catenin accumulation and WNT
gene expression. Intestinal-type adenomas and FGPs were the
results of this WNT activation. These closely mimic the lesions
observed in FAP patients. Activating one copy of b-catenin also
led to b-catenin nuclear translocation but this seemed to be a
much slower process. In the future, our inducible mouse model
may be used to dissect the importance of other genes in gastric
carcinogenesis as well as assessing the efﬁcacy of new anti-cancer
therapies.
MATERIALS AND METHODS
Ethics statement
Mouse experiments: all mouse experiments were performed under the UK
Home Ofﬁce guidelines. Human samples: formalin-ﬁxed parafﬁn-
embedded biopsy samples of intestinal-type adenomas of the stomach
with low-grade intraepithelial neoplasia were recovered from the archives
of the Institute of Pathology, Ludwig-Maximilians-Universita¨t, Mu¨nchen,
Germany. The corresponding clinico-pathological data sets were obtained
from the database. The study was performed according to the
recommendations of the local ethics committee of the Medical Faculty
of the Ludwigs-Maximilians-Universita¨t Mu¨nchen, Germany.
Mouse colonies
Outbred mice segregating for the C57BL6J and S129 genomes (ﬁve
generations C57Bl6J) were used from 8 to 12 weeks of age. The following
alleles were used: APC580Sﬂ 57, AhCreER,46 GSK3 alphaﬂ and GSK3 betaﬂ,70
Catnbexon3ﬂ,48 Z/EG,47 Rosa26lacZ,71 Lgr5-EGFP–IREScreERT2,55 Rosa26tdRFP.72
Gene deletion, tissue isolation and b-galactosidase reporter
staining
To induce recombination using the AhCreERþ construct, mice were given
four i.p. injections over 2 days of b-naphthoﬂavone (Sigma, Dorset, UK) and
tamoxifen (Sigma) in corn oil at 80mg/kg concentration each. To induce
recombination Lgr5-EGFP–IREScreERT2þ mice were given 1 i.p. injection of
3mg of tamoxifen in sunﬂower oil. At the appropriate time point or when
showing signs of illness, the mice were killed and the stomach removed
and inﬂated with 10% neutral buffered formaldehyde.73 The forestomach
was removed and the glandular stomach was cut into three sections to
give representative areas of corpus and antrum. For whole-mount b-
galactosidase (b-gal) staining, stomachs were prepared by opening,
ﬂushing with ice-cold PBS and pinning out on a wax plate. The tissue
was then ﬁxed and incubated overnight with X-gal substrate (Promega,
Southampton, UK) as described previously.74 For each time point and
genotype a minimum of three mice was used.
In-vivo imaging
In-vivo imaging of RFP ﬂuorescence within stomach tissue was performed
as follows: whole stomachs from AhCreERþ Rosa26tdRFP mice were imaged
using the Olympus OV100 molecular imaging system (Olympus, Southend-
on-Sea, UK).
Figure 5. Recombination occurs within multiple cell types in the corpus. (a) IHC detecting b-catenin showing nuclear localisation in parietal
cells (I) and foveolar cells (II) from AhCreERþ APCfl/fl mice at day 3 post-induction. Double IHC staining detecting Mcm2 (brown) and
HþKþATPase (violet) in parietal cells (III). b-Catenin (brown) and HþKþATPase (violet) in parietal cells (IV). b-Catenin (brown) and Muc5A
(violet) in foveolar cells (V). Scale bar, 10 mm. (b) ISH for Lgr5 in corpus tissue from AhCreERþ GSK3 alphafl/fl betafl/fl mice at day 12 post-
induction. Bright-field (left) and dark-field microscopy (right) images. (c) IHC detecting nuclear b-catenin in Lgr5creERT2þ Catnbexon3fl/exon3fl
(Lgr5Bcat) and Lgr5creERT2þ APCfl/fl (Lgr5 APC) mice at day 28 and 50 post-induction, respectively. Arrows indicate cells with nuclear
b-catenin that have not progressed. Scale bar, 20 mm.
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Immunohistochemistry
IHC was performed as described previously.49,75 Primary antibodies used
for IHC were anti-b-catenin (mouse monoclonal, 1:50; Transduction Labs,
Oxford, UK), anti-BrdU (mouse monoclonal, 1:500, BD Biosciences, Oxford,
UK), anti-MCM2 (rabbit, 1:500, Cell Signalling Technology, Danvers, MA,
USA), anti-Hþ–Kþ–ATPase (mouse monoclonal, 1:1000, MBL International
Corporation, Woburn, MA, USA), anti-muc 5AC (mouse monoclonal, 1:500,
Novocastra, Milton Keynes, UK), anti-Sox9 (rabbit, 1:500, Chemicon,
Watford, UK), anti-c-MYC (rabbit, 1:100, Santa Cruz, Santa Cruz, CA, USA),
anti-GFP (rabbit, 1:1000, Abcam, Cambridge, UK), anti-ki67 (rabbit, 1:250,
Thermo Fisher Scientiﬁc, Loughborough, UK), anti-Cre (rabbit, 1:1000,
Covance Research Products, Berkeley, CA, USA). For detection, the
Envisionþ system HRP Mouse and Envisionþ system HRP Rabbit
(DAKO, Cambs, UK) were used according to the manufacturer’s
instructions. For the double IHC staining, the visualisation step was
performed using the VECTOR VIP Substrate Kit and VECTOR SG Substrate
Kit (Vector Laboratories, Cambs, UK). IHC imaging was performed using a
Zeiss Axio Imager A1 microscope (EC PLAN-NEOFLUAR 40 /0.75N/0.17),
AxioCam MRC camera (Zeiss, Luton, UK) and Axiovision Rel 4.7 (Zeiss)
acquisition software.
Quantitative reverse-transcriptase PCR (qRT–PCR) and ISH
Details can be found in Supplementary Information.
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